SOURCE: SpectraScience, Inc.

February 02, 2016 09:15 ET

SpectraScience Announces Publication of Clinical Data

SAN DIEGO, CA--(Marketwired - February 02, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it had received notice that the results of an important clinical trial of the WavSTAT® Optical Biopsy System are to be published in Endoscopy magazine. The principal investigator, Dr. Helmut Neumann of the University of Erlangen in Erlangen, Germany, is a renowned gastroenterologist. Endoscopy is the premier journal for information on the latest technologies and international developments in gastrointestinal endoscopy.

"We are pleased that this seminal research has been approved for publication. The data shows quite conclusively the ability of the WavSTAT® system to exceed the clinical standards for accuracy developed and published by the American Society for Gastrointestinal Endoscopy (ASGE) for technologies and products of this kind," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "This is a key point of proof before the technology can be adopted in either the U.S. or Europe. We are conducting additional studies at various sites across Europe to reproduce and further reinforce the clinical efficacy of WavSTAT®. We expect additional studies to be published in the months to come."

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT® Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT® System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.

For more information:
Visit our web site

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information